Skip to content

Geron GERN Shares (Basic)

Shares (Basic) at other companies

Incyte logo
IncyteINCY
199.3M+2.9%
Immunome logo
ImmunomeIMNM
113.1M+42.5%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
88.3M+2.4%
Arcus Biosciences logo
Arcus BiosciencesRCUS
125.4M+27.4%
Celcuity logo
CelcuityCELC
54.5M+26.5%
Tango Therapeutics logo
Tango TherapeuticsTNGX
143.6M+30.2%

Other financials

Income statement

See full
Revenue$51.8M+30.9%
Operating income$158.0K+101%
Net income-$3.6M+81.6%
EPS (diluted)-$0.01+66.7%

Balance sheet

See full
Cash & equivalents$48.7M-12.2%
Total debt$134.0M+10.0%
Total equity$229.1M-14.6%
Total assets$534.1M-5.0%

Cash flow

See full
Operating cash flow-$62.9M-31.1%
CapEx$206.0K+2.0%
Free cash flow-$43.8M-6.8%

Valuation

See full
Market cap$878.88M-8.6%
Enterprise value$964.15M-6.2%
P/S4.7×-172×

Profitability

See full
Operating margin-705.5%-351pp
Net margin-682.5%-339pp
FCF margin-734.4%-365pp

Returns & leverage

See full
Return on equity-27.1%-7.8pp
Debt / equity0.6×+0.1×
Current ratio6.8×-1.1×

Where this comes from

Reported directly by Geron in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfSharesOutstandingBasic.

The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Geron's shares (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Geron's shares (basic)?
Geron (GERN) reported shares (basic) of 669.4K in Q1 2026.
How has Geron's shares (basic) changed year-over-year?
Geron's shares (basic) decreased by 99.9% year-over-year, from 665.9M to 669.4K.
What is the long-term trend for Geron's shares (basic)?
Over 3 years (2022 to 2025), Geron's shares (basic) has grown at a 20.5% compound annual growth rate (CAGR), from 1.5B to 2.7B.
What does shares (basic) mean?
The time-weighted average number of common shares outstanding during the period, used as the denominator for basic EPS calculations.